About This Tool

This Jakafi (ruxolitinib) Dose Calculator is an informational resource designed to assist healthcare professionals in determining appropriate starting doses and adjustments based on the official FDA prescribing information. It accounts for key patient variables including indication, baseline platelet count, organ function, and potential drug interactions.

Calculator Outputs

The calculator provides two primary outputs based on user selections:

  • Recommended Starting Dose: For new patients, the tool calculates the initial dose in mg and frequency (once or twice daily) based on the specific indication (MF, PV, aGVHD, cGVHD), baseline platelet count for Myelofibrosis, and any dose reductions required for renal/hepatic impairment or concomitant drug administration.
  • Dose Adjustment Guidance: For patients already on therapy, the tool offers guidance on whether to continue, interrupt, or modify the current dose based on updated platelet and absolute neutrophil counts (ANC), primarily for MF and PV indications.

How to Use

Follow these steps to determine the recommended Jakafi dosage:

  • Select Indication: Choose the condition being treated from the dropdown menu (e.g., Myelofibrosis). The "Baseline Platelet Count" field will appear only when MF is selected, as it is a key determinant for the starting dose in that indication.
  • Enter Patient Factors: Provide the baseline platelet count (if applicable). Select the patient's current renal and hepatic function status.
  • Identify Drug Interactions: Check the boxes if the patient is taking a strong CYP3A4 inhibitor or a low-to-moderate dose of fluconazole (≤200 mg/day).
  • Calculate Starting Dose: Click "Calculate Dose" for the recommended initial dosing regimen.
  • For Dose Adjustments: To assess a patient already on therapy, check "Calculate Dose Adjustment." Enter their current Jakafi dose and recent platelet and ANC values, then calculate.

Dosing Overview

The dosing of Jakafi is highly individualized. The initial dose depends on the indication and, for myelofibrosis, the patient's baseline platelet count. Subsequent dose adjustments are made based on safety and efficacy, particularly monitoring hematologic parameters like platelets and neutrophils.

  • Myelofibrosis (MF): Starting dose is determined by platelet count: 20 mg BID for >200 x 10⁹/L, 15 mg BID for 100-200 x 10⁹/L, and 5 mg BID for 50-<100 x 10⁹/L.
  • Polycythemia Vera (PV): The recommended starting dose is 10 mg BID.
  • Acute GVHD (aGVHD): The recommended starting dose is 5 mg BID.
  • Chronic GVHD (cGVHD): The recommended starting dose is 10 mg BID.
  • Modifications: Doses are reduced for moderate or severe renal impairment, any hepatic impairment, and co-administration with strong CYP3A4 inhibitors.

Switching Therapies

There are no specific guidelines in the prescribing information for switching from other myelosuppressive agents to Jakafi. When switching therapies, healthcare providers should use clinical judgment, considering the pharmacology of the previous agent, and may require a washout period. Careful monitoring of the complete blood count (CBC) is essential during any transition period.

Missed Dose

If a dose of Jakafi is missed, the patient should not take an additional dose to make up for it. They should take the next scheduled dose at its regular time. Taking two doses at once could increase the risk of side effects.

Safety Alerts

BLACK BOX WARNING

Jakafi carries a boxed warning for serious risks, including: Serious Infections, Increased Mortality in certain patient populations, Malignancy (such as non-melanoma skin cancer), Major Adverse Cardiovascular Events (MACE), and Thrombosis (blood clots). Patients should be closely monitored for these events. For full details, consult the most current prescribing information.

Frequently Asked Questions

  • Why is the baseline platelet count required for Myelofibrosis but not other indications?
    For MF, the starting dose is directly tied to the baseline platelet count to manage the risk of thrombocytopenia, a common side effect. For PV and GVHD, a fixed starting dose is recommended.
  • What happens if a patient on hemodialysis needs Jakafi?
    For patients with End-Stage Renal Disease (ESRD) on hemodialysis, the dose is typically reduced and administered as a single dose once daily, specifically after the dialysis session.
  • How does a strong CYP3A4 inhibitor affect the Jakafi dose?
    These inhibitors significantly increase ruxolitinib exposure. The calculator will recommend a 50% dose reduction for doses of 10 mg BID or greater. For a 5 mg BID dose, it recommends switching to 5 mg once daily.
  • Why does the tool ask for current platelet and ANC counts for dose adjustments?
    For patients on therapy, Jakafi doses must be held or reduced if platelet counts fall below 50 x 10⁹/L or the Absolute Neutrophil Count (ANC) falls below 0.5 x 10⁹/L. This is a critical safety monitoring parameter.
  • Can this calculator be used for pediatric patients?
    No. This tool is based on the dosing guidelines for adults. Jakafi is approved for pediatric patients 12 years and older with GVHD, but dosing may differ and should be managed by a specialist.
  • What is the maximum recommended dose for Jakafi?
    The maximum recommended starting dose for MF is 20 mg BID. Doses should not be increased above 25 mg BID.
  • Why does hepatic impairment lead to a dose reduction?
    Ruxolitinib is metabolized by the liver. In patients with any degree of hepatic impairment (Child-Pugh A, B, or C), drug clearance is reduced, leading to higher exposure. A lower starting dose is recommended to mitigate potential toxicity.
  • What should I do if the calculator result seems incorrect?
    This tool is for informational purposes only and does not replace clinical judgment. Always verify calculations against the most recent FDA-approved prescribing information before making any clinical decisions.

References

PRO
Ad-Free Access
$3.99 / month
  • ✓ No Interruptions
  • ✓ Faster Page Loads
  • ✓ Support Content Creators
Subscribe Now